COMMUNIQUÉS West-GlobeNewswire

Longeveron® Announces Contract Development and Manufacturing Business and First Contract
03/06/2024
Contract manufacturing services as a new business line has the potential to generate approximately $4-5 million in annual revenues First manufacturing services contract signed with Secretome Therapeutics MIAMI, June 03 [...]
Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting
03/06/2024
Company presents results from in vivo studies of PT-CD16VS, a genetically modified allogeneic cell therapy derived from human placental circulating T (P-T) cells, in combination with various monoclonal antibodies [...]
LIXTE Biotechnology Holdings Names Distinguished Oncologist Jan Schellens as Chief Medical Officer
03/06/2024
PASADENA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer [...]
electroCore, Inc. Announces $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
03/06/2024
ROCKAWAY, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to [...]
FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 HALO Clarity™ Headset Device
03/06/2024
Clinical studies in anxiety and insomnia expected to commence in the third quarter of 2024 HOUSTON, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) [...]
Safety Shot, World’s First Beverage to Reduce Blood Alcohol Content, Announces Launch of New 4-Ounce Bottles
03/06/2024
Innovative Formula To Be Available in Portable Format for Enhanced Accessibility and Convenience JUPITER, FL, June 03, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company), announced today the launch [...]
Microbot Medical Has Received FDA Approval to Proceed with its Pivotal Human Clinical Trial
03/06/2024
The trial will be conducted in the U.S. and its results will complement the preclinical data on the LIBERTY® Endovascular Robotic Surgical System, which together are expected to support a future 510(k) submission [...]
TECVAYLI®▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma
03/06/2024
New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing 1 Separate analyses from the MajesTEC-1 and OPTec studies are the [...]
Autonomix Announces Approval of Protocol Amendment by Ethics Committee Upon Completion of All Lead-In Patients in Ongoing Human Clinical Trial
03/06/2024
Company plans to release topline results from “lead-in” patients (n=5) imminently THE WOODLANDS, TX, June 03, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical [...]
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
03/06/2024
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a biopharmaceutical company [...]
Molecular Templates, Inc. Provides Interim Update
03/06/2024
Continued monotherapy activity in solid tumors with MT-6402 (PD-L1-targeting ETB) in checkpoint-experienced patients. Early pre-clinical and clinical data demonstrate the potential of MT-0169 (CD38-targeting ETB) in [...]
NKGen Biotech To Present Updated Phase 1 Data on SNK02 Allogeneic NK Cell Therapy in Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
03/06/2024
SANTA ANA, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (Nasdaq: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative [...]
InnovAge PACE Recertified as a Great Place to Work
03/06/2024
PACE Program Provides Highly Coordinated, Personalized Senior Care DENVER, June 03, 2024 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare [...]
Noom Launches Noom Vibe, a Wellness Community and Habit Tracker Built for the Age of GLP-1s
03/06/2024
Wellness App incentivizes healthy habits critical to whole-person health and longevity Answers Surgeon General Murthy’s call to integrate social connection into healthcare NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- [...]
Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference
03/06/2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare [...]
Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
03/06/2024
New study data confirmed previous ColoFuture and eAArly DETECT study performance with sensitivity for CRC of 92% and 82% for advanced adenomas, including 95.8% detection of high-grade dysplasia Results from pooled study [...]
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
03/06/2024
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a [...]
Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies
03/06/2024
START is a pilot program newly launched jointly by the FDA CDER and CBER divisions to further accelerate the development of novel drug and biological products for rare diseases DNL126 was selected as one of three CDER- [...]
BriaCell Presents Clinical Efficacy Data at ASCO 2024
03/06/2024
BriaCell doubles Progression-Free-Survival (PFS) and Clinical Benefit Rate vs historical results in the literature Bria-IMT™ PFS compares favorably to PFS of most recent treatment in 48% of Antibody-Drug Conjugate (ADC [...]

Pages